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Abstract The localization of prostaglandin D receptor in the 
mouse brain was examined by in situ hybridization histochem-
istry. The autoradiography showed significant hybridization 
signals of mRNA for prostaglandin D receptor in the leptome-
ninges covering the surface of the brain, but not in neurons or glia 
in the brain parenchyma. This finding was confirmed by 
Northern blot analysis using mRNA prepared from either the 
whole brain with the leptomeninges, brain parenchyma without 
the leptomeninges or the leptomeninges alone. A weak signal 
corresponding to the major 3.5-kbp transcript was detected in the 
whole brain. This band was significantly enriched in the 
leptomeninges, but was not detected in the brain parenchyma. 
These results suggest that prostaglandin D receptor is most 
highly, if not exclusively, expressed in the leptomeninges of the 
mouse brain. 
© 1997 Federation of European Biochemical Societies. 
Key words: In situ hybridization; Northern blot analysis; 
Prostaglandin D2; Prostaglandin D receptor; Leptomeninx; 
Mouse brain 
1. Introduction 
Prostanoids, including prostaglandins (PGs) and thrombox-
anes, exert a variety of effects which maintain local homeo-
stasis in the body [1]. They are synthesized upon stimulation, 
released immediately after synthesis, and act on surface recep-
tors of cells in the vicinity to elicit their actions [2]. Among 
them, PGD2 is a prostanoid, the physiological functions of 
which are least known. The most characterized PGD2 action 
is anti-aggregatory activity on human platelets. PGD2 is pro-
duced during platelet aggregation and works as a negative 
feedback modulator [3]. The receptor for PGD2 (DP receptor) 
mediating this activity has been characterized and several syn-
thetic agonists and antagonists have been developed (for re-
view see [4]). However, this activity is limited to a few species 
of mammals and is not seen in others including rodents [5]. 
PGD2 is also synthesized and released during allergic chal-
lenge by activated mast cells [6]. This synthesis is catalyzed 
by mast cell-specific glutathione-requiring PGD synthase [7]. 
However, the target cells and the role of PGD2 in allergic 
reactions remain unknown. PGD2 is also one of the major 
PGs synthesized in the brain, and much attention has been 
paid to its possible physiological functions in the central nerv-
ous system [8]. Exogenous PGD2 administered into the brain 
and the spinal cord exerts several actions such as sleep induc-
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tion [9], hypothermia [10], modulation of olfactory function 
[11] and of LH-RH release [12], and analgesia [13]. However, 
the properties and localization of the receptor mediating these 
actions remain unknown. This knowledge may be essential to 
the elucidation of the physiological significance of PGD2 and 
its actions in the brain. Recently, the DP receptor of mice [14] 
and humans [15] has been cloned. These receptors show phar-
macological properties consistent with the DP receptor previ-
ously characterized in platelets and other systems [16]. North-
ern blot analysis of their mRNA expression, however, 
revealed very low expression in the brain. To clarify the ap-
parent discrepancy between receptor expression and the re-
ported actions of PGD2 in the brain, we carried out an in 
situ hybridization study to examine localization of the DP 
receptor in the mouse brain. 
2. Materials and methods 
2.1. In situ hybridization 
2.1.1. Synthesis of cRNA probes. An antisense cRNA probe for 
the mouse DP receptor was prepared as follows. A 1.2-kbp fragment, 
PGc9 [14], a functional cDNA encoding the mouse DP receptor, was 
subcloned into pBluescript SK(—) (Stratagene). After linearization 
with EcoRV, it was used as a template for riboprobe synthesis. An 
antisense riboprobe for in situ hybridization analysis was prepared by 
transcription with T3 RNA polymerase (Promega) in the presence of 
[a-35S]CTP to a specific activity of 1.0 X109 dpm/ug. The cold anti-
sense riboprobe was synthesized by the same procedure using unla-
beled nucleotides. After unincorporated nucleotides were removed, 
riboprobes were degraded to ~150 bases by alkaline hydrolysis. 
2.1.2. Preparation of tissue sections and hybridization reaction. A-
dult male ddY mice were anesthetized with diethyl ether and decapi-
tated. The brains were removed, immediately frozen in isopentane at 
—50°C, and then cut into coronal or sagittal sections 8 urn thick on a 
cryostat. These consecutive sections covered the whole brain. The 
sections were then thaw-mounted onto poly-L-lysine (Sigma) coated 
slides. They were briefly air-dried and kept at — 80°C until use. 
The frozen sections were warmed to room temperature, fixed with 
4% formaldehyde in phosphate-buffered saline for 10 min, rinsed in 
phosphate-buffered saline, and then acetylated with 0.25% acetic an-
hydride in 0.1 M triethanolamine and 0.9% NaCl for 10 min at room 
temperature. After dehydration in an ascending ethanol series, the 
sections were air-dried and stored at —80°C until use. Hybridization 
was carried out in 10 mM Tris-HCl, pH 7.5 containing 50% form-
amide, 2XSSC, ixDenhardt's solution, 10% dextran sulfate, 0.2% 
sodium dodecyl sulfate (SDS), 100 mM dithiothreitol (DTT), 500 
ug/ml sheared single-stranded salmon sperm DNA (ssDNA) and 
250 ug/ml yeast transfer RNA (tRNA). The riboprobe, preheated at 
80°C for 10 min in 1 M DTT, was added to the hybridization buffer 
at 7 X104 dpm/ul. After the hybridization solution was applied, the 
sections were covered with a coverslip and sealed with rubber cement. 
After incubation at 57°C for 6 h, the slides were immersed at room 
temperature in 2 X SSC to remove the coverslips, and then washed for 
1 h in 2XSSC containing 10 mM ß-mercaptoethanol. They were then 
warmed from room temperature to 60°C and cooled back to room 
temperature. The sections were then treated with 20 ug/ml ribonu-
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clease A in 10 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 1 mM ethylenedi-
amine tetraacetic acid for 30 min at 37°C, followed by an additional 
wash in 0.1 X SSC at 60°C for 1 h. After dehydration in an ascending 
ethanol series, the slides were air-dried and exposed to ß-Max film 
(Amersham) for 7 days at room temperature, or were dipped in NTB 
2 (Kodak), a nuclear track emulsion which was diluted 1:1 with dis-
tilled water. After exposure for 30 days at 4°C, the dipped slides were 
developed in D-19 developer (Kodak), fixed, and counterstained with 
1% cresyl violet. 
2.2. Northern blot analysis 
DDY mice were killed by cervical dislocation and the brains were 
carefully removed so that the leptomeninges remained intact as much 
as possible. The leptomeninges, composed of the pia mater and the 
arachnoid membrane, were then peeled off with forceps under micros-
copy, and pooled. The remainder of the brain was used as brain 
parenchyma. Total RNA was isolated from the whole brain, brain 
parenchyma and the leptomeninges using the AGPC method, and 
poly(A)+ RNA was prepared using Oligotex dT30 (Takara, Japan). 
A cRNA probe was synthesized as described in Section 2.1.1 using 
[oc-32P]UTP instead of [a-32P]CTP. Hybridization was carried out at 
70°C in 5XSSC, 50% formamide, 5xDenhardt's solution, 0.2% SDS, 
250 ug/ml heat-denatured ssDNA, 200 |ig/ml yeast tRNA and 5 ng/ml 
of cRNA probe. The filter was washed in O.lxSSC, 0.1% SDS at 
70°C for 20 min, treated with 1 ng/ml RNase A in 2XSSC for 10 
min at room temperature, and washed again in 0.1 XSSC, 0.1% SDS 
at 70°C for 20 min. The filter was exposed to X-ray film (Konica, 
Japan) for 12 h. 
3. Results and discussion 
We previously performed in situ hybridization to study ex-
pression of PGE receptor EP3 subtype mRNA and revealed 
that this receptor is expressed in a variety of nuclei in the 
mouse brain [17]. We employed a similar procedure to exam-
ine the regional distribution and cellular localization of DP 
receptor mRNA in the brain with particular attention to those 
areas such as the preoptic area, hypothalamus and olfactory 
bulb where PGD2 is thought to exert the reported actions. 
However, we could not observe specific signals in any nuclei 
in these and other areas of the mouse brain. Instead, in the 
film autoradiography, we detected weak but significant signals 
discontinuously covering the surface of the brain in both sag-
ittal and coronal sections (Fig. la,b). This labeling was more 
evident in the coronal sections of the olfactory bulb, where 
intense signals were found in the inter-hemispheric region 
(Fig. lb,d). This signal appeared specific, because it was ab-
sent in a neighboring section incubated in the presence of an 
excess of unlabeled probe (Fig. lc). In the emulsion-dipped, 
counterstained sections, it was confirmed that the hybridiza-
tion signals were localized in the leptomeninges covering the 
brain (Fig. 2), and that no specific signals were distributed on 
neurons or glia in the brain parenchyma. Localization of sig-
nals in the leptomeninges could explain the discontinuity of 
the signal on the brain surface and its enrichment in the inter-
hemispheric region, because the leptomeninges tend to detach 
from the brain during sample preparation. 
While the above findings suggest the expression of DP re-
ceptor in the leptomeningeal cells, it is also known that radio-
active probes tend to accumulate along the cutting edges of 
tissue samples. In order to exclude the possibility of this so-
called edging effect, we examined DP receptor expression in 
the isolated leptomeninges by Northern blot analysis, and 
compared it with the expression levels in whole brain with 
the leptomeninges and in the brain parenchyma (Fig. 3). Con-
sistent with the previous findings [14], only a very faint hy-
bridization signal was detected in the whole brain. This 3.5-
kbp signal corresponding to the previously detected transcript 
in peripheral tissues [14] was very much enriched in the lep-
tomeninges. In addition, minor hybridization bands were de-
tected at 0.5, 2.0 and 6.0 kbp in this tissue. The expression 
level in the leptomeninges was much higher than that found in 
any other tissues reported in the previous study [14] (data not 
shown). In contrast, no hybridization signals were found in 
the brain parenchymal fraction in the present analysis. 
The present study has thus revealed that the DP receptor is 
most highly expressed in the leptomeninges of the mouse 
brain. We cannot, of course, exclude the possibility that the 
DP receptor is also expressed by neurons and glia at levels 
Fig. 1. Negative film images of in situ hybridization analysis of the mouse brain. Sections were hybridized with 35S-labeled antisense riboprobe 
in the absence (a, b and d) or presence (c) of a 100-fold excess of the unlabeled probe. Panel a is shown in a sagittal plane approximately 0.3 
mm lateral to the midline. Panel b is a transverse section of the olfactory bulb, which is located about 3.3 mm anterior to bregma indicated by 
an arrow in a. Panel c is the section adjacent to b, and panel d shows a higher magnification of the inter-hemispheric region shown in b. Bar, 
3 mm for a, 1.7 mm for b and c, and 650 um for d. 
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undetectable by the current methods, and that the receptor in 
the brain may be upregulated by certain stimuli. However, the 
DP receptor, if present in the brain, is at a level much lower 
than that found for the EP3 receptor. Interestingly, Urade et 
al. [18] recently examined the localization of brain-specific 
PGD synthase by both immunohistochemistry and in situ 
hybridization and found that it is expressed abundantly in 
the leptomeninges and the choroid plexus. Thus, the enzyme 
responsible for PGD2 synthesis and the receptor for this PG 
are both expressed in the leptomeninges, although no expres-
sion of the receptor mRNA was detected in the choroid 
plexus. This may indicate that the enzyme and the receptor 
are expressed by different types of cells in the leptomeninges. 
In any event, these findings taken together suggest that PGD2 
produced by cells in the leptomeninges acts in an autocrine or 
paracrine way on cells in the leptomeninges. It is not known 
what central action of PGD2 is mediated by the DP receptor 
in the leptomeninges. Interestingly, Matumura et al. examined 
the site of the sleep inducing action of PGD2 by microinject-
ing the PG into various parts of the brain and found that it 
induces sleep more effectively when injected into the subar-
achnoid space than when injected into the brain parenchyma. 
From these studies, they concluded that PGD2 acts on the 
ventral surface of the rostral basal forebrain [19]. However, 
no expression of DP receptor mRNA was detected in the 
parenchyma of the brain in this area. On the other hand, 
the leptomeninges are markedly thick in this area with high 
levels of signals for DP receptor mRNA. It is possible, there-
fore, that PGD2 injected into the subarachnoid space of this 
region works on the DP receptor in the leptomeninges to 
induce sleep. If this is the case, these observations suggest a 
new mode of regulation of brain function in which humoral 
factor released by the leptomeninges is delivered to the brain 
and affects its function. The leptomeninges are located in a 
strategic position between the peripheral circulation and the 
brain and may mediate the transmission of blood-borne sig-
nals such as cytokines to the brain by this mode of regulation. 
We have recently succeeded in preparing DP-deficient knock-
out mice. The above hypothesis and the possible involvement 
Fig. 2. Localization of DP receptor mRNA in the leptomeninges. A 
dark-field photomicrograph of the coronal section 1.2 mm posterior 
to bregma is shown in panel a, and a higher magnification bright-
field photomicrograph of a ventral area (indicated by an arrow in 
a) of the adjacent section is shown in b. Bar, 1.7 mm for a and 100 
um for b. 
Fig. 3. Northern blot analysis of DP receptor mRNA in the mouse 
brain. Poly(A)+ RNAs were isolated from the brain with or without 
the leptomeninges and from the leptomeninges themselves, and 5 ug 
of each RNA was applied to gel electrophoresis. After transfer to a 
membrane, hybridization was carried out using a 32P-labeled anti-
sense cRNA probe as described in Section 2. Lane 1, brain with the 
leptomeninges. Lane 2, leptomeninges. Lane 3, brain without the 
leptomeninges. 
of the DP receptor studied here in sleep induction will be 
tested by the analysis of these DP-deficient mutant mice. 
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